The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Mazen Noureddin, Winston Dunn, Rashmee Patil, Dimple Desai, Rohit Puskoor, Jaehee Shin, Dennis To, Adam C Bell, Daniel R Lee, Yen-Huei Lin, Seulki Lee

Open source

DOI: 10.1016/s2468-1253(26)00130-5
Published: 2026-10
Container: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-26-00130-5,
  title = {The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial},
  author = {Mazen Noureddin and Winston Dunn and Rashmee Patil and Dimple Desai and Rohit Puskoor and Jaehee Shin and Dennis To and Adam C Bell and Daniel R Lee and Yen-Huei Lin and Seulki Lee},
  year = {2026},
  journal = {The Lancet Gastroenterology \&amp; Hepatology},
  doi = {10.1016/s2468-1253(26)00130-5},
  url = {https://doi.org/10.1016/s2468-1253(26)00130-5}
}

RIS

TY  - JOUR
TI  - The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial
AU  - Mazen Noureddin
AU  - Winston Dunn
AU  - Rashmee Patil
AU  - Dimple Desai
AU  - Rohit Puskoor
AU  - Jaehee Shin
AU  - Dennis To
AU  - Adam C Bell
AU  - Daniel R Lee
AU  - Yen-Huei Lin
AU  - Seulki Lee
PY  - 2026
JO  - The Lancet Gastroenterology &amp; Hepatology
DO  - 10.1016/s2468-1253(26)00130-5
UR  - https://doi.org/10.1016/s2468-1253(26)00130-5
ER  -

APA

Noureddin, M., Dunn, W., Patil, R., Desai, D., Puskoor, R., Shin, J., To, D., Bell, A. C., Lee, D. R., Lin, Y., & Lee, S. (2026). The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00130-5

Source records

crossref · retrieved 2026-09-26T02:00:25.117Z